

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

May 14, 2018

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1), 52(4) and 52(5) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The Unaudited Financial Results of the Company for the half year and year ended 31st March, 2018 along with the Limited Review Report for that period issued by the Statutory Auditors pursuant to Regulation 52(1) of SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015 (Annexure 1).
- iii. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015 (Annexure 2).

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Susheel Koul
Managing Director
DIN: 00925887





To,
The Board of Directors,
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Mumbai

Dear Sir,

Re: Limited Review of Un-audited Financial Results for the Half Year ended 31st March 2018 in respect of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Introduction

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Genlink Pharma Solutions Private Limited ("the Company") (Formerly Genlink Pharma Investments Private Limited) for the half year ended 31st March 2018 ("the statement"). This statement is the responsibility of the Company's management and has been prepared in terms of Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/IMD/DFI/69/2016 dated August 10, 2016.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review of Interim Financial Information performed issued by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/IMD/DFI/69/2016 dated August 10, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS
Firm Registration No. 109901W/W100082

Place : MUMBAI
Dated : 14/05/2018

Shankarlal Agrawal
PARTNER
M. No. 72184



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

Standalone Unaudited Financial Results for the Half Year and Year ended 31st March 2018

INR

Sr. No.	Particulars	Half Year Ended		Year to date ended	Previous Year Ended
		31-Mar-18	31-Mar-17	31-Mar-18	31-Mar-17
		Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations				
(i)	Net Sales/Income from Operations (Net of excise duty)	-	1,750,000	-	1,750,000
(ii)	Other Income	-	-	-	-
	Total Income from Operations	-	1,750,000	-	1,750,000
2	Expenses				
(i)	Cost of Material Consumed	-	-	-	-
(ii)	Purchase of Stock in trade	-	-	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-	-	-
(iv)	Employee Benefits Expenses	-	-	-	-
(v)	Depreciation and Amortization Expenses	-	-	-	-
(vi)	Finance Cost	14,650	1,533,783	18,539	1,538,265
(vii)	Other Expenses	348,045	1,779,622	505,728	1,894,885
	Total Expenses	362,695	3,313,405	524,267	3,433,150
3	Profit/(Loss) from operation before tax	(362,695)	(1,563,405)	(524,267)	(1,683,150)
4	Tax Expenses	30,680	531,830	30,680	531,830
5	Profit/(Loss) from ordinary activities for the period	(393,375)	(2,095,235)	(554,947)	(2,214,980)
6	Other Comprehensive Income				
(i)	Items that will not be reclassified to profit or loss	-	-	-	-
(ii)	Items that will be reclassified to profit or loss	-	-	-	-
	Total Comprehensive Income/(Loss) for the period	(393,375)	(2,095,235)	(554,947)	(2,214,980)
7	Paid up Equity Share Capital of 10/- each	100,000	100,000	100,000	100,000
8	Earning per Share(not annualised)				
	Basic	-39.34	-231.75	-55.49	-244.99
	Diluted	-39.34	-231.75	-55.49	-244.99

For Genlink Pharma Solutions Private Limited



Susheel Koul

Susheel Koul
Managing Director
DIN: 00925887

Date: 14th May 2018
Place: Navi Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

Statement of Standalone Assets & Liabilities as on 31st March, 2018

INR

Sr. No.	PARTICULARS	As On 31-Mar-18 Unaudited	As On 31-Mar-17 Audited
	ASSETS		
	Non Current Assets		
1	Property, plant and Equipment		
2	Investment Property	-	-
3	Intangible Assets	-	-
4	Financial assets (others)	-	-
5	Non current tax assets (Net)	-	-
6	Other Non current assets	248,995,479	248,995,479
	Total Non-current assets	248,995,479	248,995,479
	Current Assets		
1	Financial assets	-	-
2	Investments	-	-
3	Trade and other receivables	-	-
4	Cash and cash equivalents	23,387	1,115,612
5	Other financial assets	-	-
6	Other current assets	45,198	-
	Total Current assets	68,585	1,115,612
	TOTAL ASSETS	249,064,064	250,111,091
	EQUITY AND LIABILITIES		
	Equity		
1	Equity Share Capital	100,000	100,000
2	Other Equity	(2,769,928)	(2,214,980)
	Total Equity	(2,669,928)	(2,114,980)
	Non-current Liabilities		
1	Financial liabilities		
	(a) Long-term borrowings	250,150,000	250,000,000
	(b) Other Financial Liabilities	-	-
2	Long term Provision	-	-
3	Deferred Tax Liabilities (net)	-	-
4	Other Non-current Liabilities	-	-
	Total Non-current Liabilities	250,150,000	250,000,000
	Current Liabilities		
1	Financial Liabilities		
	(a) Trade and Other payables	-	-
	(b) Other financial liabilities	-	-
2	Short term provisions	50,000	408,830
3	Other current liabilities	1,533,992	1,817,241
	Total Current Liabilities	1,583,992	2,226,071
	TOTAL EQUITY AND LIABILITIES	249,064,064	250,111,091



For Genlink Pharma Solutions Private Limited

(Signature)

Susheel Koul
Managing Director
DIN: 00925887

Date: 14th May 2018

Place: Navi Mumbai

Notes:-

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 14 2018.
2. As the Company's business activity falls within single segment, the disclosure requirement of IND AS 108-Operating Segment is not applicable.
3. (i) Debt Equity Ratio: Not applicable (Due to negative net worth)
(ii) Debt Service Coverage Ratio: Not Applicable (Due to Net Loss)
(iii) Interest Service Coverage Ratio: Not Applicable (Due to Net Loss)
(iv) Net worth of the Company is Negative Rs. 2,669,928.
(v) The company has maintained 100% asset cover for non-convertible debentures issued by it,
4. In the absence of profits as per section 71(4) of the Companies Act 2013, the Company has not created Debenture Redemption Reserve.
5. Reconciliation of Net profit as reported under previous Indian Generally Accepted Accounting Principles(Indian GAAP) to Ind AS:

Particulars	Half year ended March 31, 2017	Year ended March 2017
Net Loss as per Indian GAAP	(2,095,235)	(2,214,980)
Adjustment:-	NIL	NIL
Net Profit/(Loss) as per IND AS	(2,095,235)	(2,214,980)

6. Results for the half year ended March 31, 2018 are in compliance with Indian Accounting Standards (Ind AS) in terms of SEBI's circular bearing no CIR/IMD/DF1/69/2016 dated August 10, 2016.
7. Pursuant to the terms of Debenture Trust Deed (DTD) executed between the Company and the Debenture Trustee, the required security on pari passu basis on the following assets of the Company as specified in the aforesaid DTD have been created and maintained in respect of Secured Redeemable Non-convertible Debentures issued by the Company:
 - a) 413,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Company.
 - b) 80,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
 - c) 80,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.
8. Previous year figures have been regrouped/reclassified whenever necessary.

Place: Navi Mumbai

Date: 14th May 2018.



The image shows a handwritten signature in black ink over a circular purple stamp. The stamp contains the text "Genlink Pharma Solutions Pvt. Ltd." around the perimeter and a star symbol in the center.

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Annexure 1

With reference to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 please find the disclosure as on half year ended 31st March, 2018 as under:

- Credit rating** - The Company's NCDs have been rated as "SMERA BB-" by SMERA Ratings Limited. There has been no change in the credit rating of the Company.
- Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
- Debt-equity ratio** - Not applicable (due to negative net worth)
- Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
- Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
- Next due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence no due date is applicable.
- Debt service coverage ratio** - Not Applicable (due to Net Loss)
- Interest service coverage ratio** - Not Applicable (due to Net Loss)
- Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares
- Capital redemption reserve/debenture redemption reserve** - NIL
- Net worth** - The net worth of the Company is Rs 2,669,928/-
- Net profit/loss after tax**
Net loss after tax of the Company is Rs 393,375/-
- Earnings per share**
Earnings per share of the Company is negative Rs 39.34



Susheel Koul
Managing Director
DIN: 00925887



Office: 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email genlinkinfo@gmail.com www.genlinkpharma.com

CIN: U74110 MH 2016 PTC 280765

May 14, 2018

To,
Mr. Susheel Koul
Managing Director,
Genlink Pharma Solutions Private Limited
Office No - 1704, 17th Floor, Kesar Solitaire,
Plot No. 5, Sector 19,
Sanpada , Navi Mumbai,
Mumbai – 400 705.

Dear Sir,

Sub: Certificate of Debenture Trustee under Regulation 52(5) of SEBI (LODR) Regulations, 2015 for March 31, 2018.

In compliance with the requirements of Chapter V, Regulation 52, Sub – Regulation (4) and (5) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Non – Convertible Debt Securities we would like to state as under:

We, Vistra ITCL (India) Limited (formerly known as IL&FS Trust Company Limited), are acting as a Debenture Trustee for the debenture programme of Rated, Listed, Redeemable, Non-Convertible Debenture (NCDs) issue aggregating to Rs.25 Crores of Genlink Pharma Solutions Private Limited (Formerly known as Genlink Pharma Investment Private Limited).

With reference to above, we have received the following documents and have noted its contents:

1. Un-Audited Financial results for the half year ended March 31, 2018 along with the Limited Review Report.
2. Disclosure pursuant to Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015 for the year ended March 31, 2018 (*Annexure 1*).

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You

Yours sincerely,

For Vistra ITCL (India) Limited
(Formerly known as IL&FS Trust Company Limited)


Jatin Chonani
Compliance Officer

Place: Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

May 14, 2018

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 54(2) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please note that the Company maintains as on half year ended 31st March, 2018 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 4,13,497 Equity shares of Enaltec Labs Pvt. Ltd. held by the Company.
2. 80,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 80,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Susheel Koul
Managing Director
DIN: 00925887



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

May 14, 2018

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Statement of material deviation under Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015

Dear Sir/Madam,

With reference to Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 we hereby state that for the half year ended 31st March, 2018, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Susheel Koul
Managing Director
DIN: 00925887

